Personalis, Inc. (PSNL) is a Healthcare stock trading at $10.52 (as of 2026-06-18), with a market capitalization of $1.19B and a trailing P/E of -11.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Personalis, Inc. provides cancer genomics sequencing and analytical services, including its NeXT platform for profiling tumors or tumor signals from limited tissue or plasma samples and for related biomarker and neoantigen analysis, and its ACE platform for clinical and therapeutic applications. It serves biopharmaceutical companies, academic institutions, non-profits, and government entities.